Manufacturing and Quality
Disclaimer: GSK does not support or promote monotherapy use of SABA. Ventolin/SABA is indicated for the treatment and/or prevention of bronchospasms8 SABAs should not be the only or main treatment in patients with asthma8. SABAs should be used appropriately with regular ICS-containing therapies as prescribed; on-demand use of SABA should not exceed 4 times daily as this may indicate deteriorating asthma control8.
Ventolin safety information1
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني www.moh.gov.om : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor. All rights reserved.